<DOC>
	<DOCNO>NCT00214864</DOCNO>
	<brief_summary>The purpose study attempt find well tolerate dos schedule highly effective combination chemotherapy regimen .</brief_summary>
	<brief_title>A Study Weekly Taxotere Xeloda Metastatic Breast Cancer</brief_title>
	<detailed_description>Combination chemotherapy advantage monochemotherapy due high response rate often obtain ; use agent non-overlapping toxicity profile , response achieve less toxicity maximally tolerated dos single agent . One significant advantage capecitabine/weekly docetaxel combination chemotherapy agent appear toxicity profile appropriate palliative therapy advance breast cancer . This trial utilize usual schedule capecitabine use USA , two time per day oral dose 14 day reduce dose hope decrease toxicity . Docetaxel give weekly dose 35 mg/m2 X 2 one-week rest coincide 14-day schedule capecitabine . The primary objective evaluate overall response rate ( complete partial response ) accord RECIST criterion combination capecitabine docetaxel select schedule patient advance and/or metastatic breast cancer . The secondary objective evaluate tolerability , time tumor progression , time treatment failure combination capecitabine docetaxel .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Female patient histopathologically proven metastatic breast cancer . Patients 1875 year old Performance status : Karnofsky &gt; 70 % Patients must measurable disease . Patients blastic bone lesion ineligible . Adequate bone marrow , liver , renal cardiac function define : Ability understand study give inform consent . Patients may receive one prior chemotherapy metastatic breast cancer . 5FU Taxol give part adjuvant regimen render patient ineligible . Patients brain metastasis , adequately treat stable require continued steroid medication eligible progression &gt; 3 month . Patients receive anticancer investigational agent month prior inclusion . Patients previously treat docetaxel ( Taxotere ) capecitabine ( Xeloda ) . Patients lack physical integrity upper gastrointestinal tract , inability swallow tablet malabsorption syndrome . Patients renal impairment ( creatinine clearance 30 ml/min calculate accord Cockcroft Gault , see Appendix D ) , since capecitabine contraindicate patient severe renal impairment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Taxotere ( docetaxel )</keyword>
	<keyword>Xeloda ( capecitabine )</keyword>
</DOC>